8-K: Cencora Reports Strong Q4 and Fiscal Year 2024 Results, Announces Dividend Increase and Acquisition

Cencora's Q4 2024 revenue reached $79.1 billion, a 14.7% year-over-year increase, with adjusted diluted EPS of $3.34, and the company also announced an 8% increase in its quarterly dividend.

Summary

• Cencora reported a 14.7% increase in revenue for the fourth quarter of fiscal year 2024, reaching $79.1 billion.
• The company's full fiscal year 2024 revenue was $294.0 billion, a 12.1% increase year-over-year.
• GAAP diluted earnings per share (EPS) for the quarter was $0.02, while adjusted diluted EPS was $3.34, a 16.8% increase.
• For the full fiscal year, GAAP diluted EPS was $7.53, and adjusted diluted EPS was $13.76, a 14.8% increase.
• The company's board of directors increased the quarterly dividend by 8% to $0.55 per share.
• Cencora announced the acquisition of Retina Consultants of America (RCA) to further its specialty leadership.
• The company is projecting fiscal year 2025 adjusted operating income growth of 5% to 6.5% and adjusted diluted EPS growth of 8% to 10%.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with strong revenue and adjusted earnings growth, a dividend increase, and a strategic acquisition. However, the significant GAAP losses and increased operating expenses temper the overall sentiment slightly.

Positives

• Cencora experienced significant revenue growth in both the fourth quarter and the full fiscal year 2024.
• Adjusted diluted EPS showed strong growth in both the fourth quarter and the full fiscal year.
• The company increased its quarterly dividend by 8%, demonstrating confidence in its financial position.
• The acquisition of Retina Consultants of America is expected to strengthen Cencora's position in the specialty healthcare market.
• Cencora's fiscal year 2025 guidance indicates continued growth in revenue, operating income, and earnings per share.

Negatives

• GAAP diluted EPS for the fourth quarter was only $0.02, a significant decrease compared to the prior year due to a goodwill impairment charge.
• GAAP diluted EPS for the full fiscal year decreased by 11.7% to $7.53.
• Operating expenses increased significantly in the fourth quarter, primarily due to a $418 million goodwill impairment charge related to PharmaLex and increased litigation expenses.
• Gross profit margin declined in the U.S. Healthcare Solutions segment due to increased sales of lower-margin GLP-1 products and the absence of high-margin COVID-19 therapy sales.
• Operating income decreased by 73.4% in the fourth quarter due to increased operating expenses.

Risks

• The goodwill impairment charge related to PharmaLex significantly impacted GAAP earnings.
• Increased operating expenses, including litigation and opioid-related expenses, are a concern.
• The decline in gross profit margin in the U.S. Healthcare Solutions segment due to product mix changes could impact future profitability.
• The company's future performance is subject to uncertainties and changes in circumstances, as noted in the cautionary note regarding forward-looking statements.
• The company's fiscal year 2025 guidance does not include the impact of the RCA acquisition, which could affect future results.

Future Outlook

Cencora expects fiscal year 2025 revenue growth of 7% to 9%, adjusted operating income growth of 5% to 6.5%, and adjusted diluted EPS growth of 8% to 10%.

Management Comments

• Bob Mauch, President and Chief Executive Officer of Cencora, stated that the company took important steps forward in fiscal 2024, evolving its global enterprise and executing on its strategy.
• Mr. Mauch also mentioned that the acquisition of Retina Consultants of America furthers the company's ability to build on its leadership in specialty.
• Mr. Mauch emphasized that Cencora is well-positioned for continued growth and committed to long-term value creation for all stakeholders.

Industry Context

Cencora's results reflect the ongoing trends in the pharmaceutical distribution and healthcare solutions industry, including increased demand for specialty products and the impact of new drug classes like GLP-1s. The acquisition of RCA aligns with the industry's focus on expanding specialty care services.

Comparison to Industry Standards

• Cencora's revenue growth of 12.1% for fiscal year 2024 is strong compared to the overall pharmaceutical distribution market, which has seen moderate growth.
• The adjusted diluted EPS growth of 14.8% is also a positive indicator, suggesting efficient operations and cost management.
• Compared to competitors like McKesson and Cardinal Health, Cencora's focus on specialty solutions and strategic acquisitions positions it for continued growth.
• The company's investment in technology and data analytics, as evidenced by the appointment of a Chief Data and Information Officer, is in line with industry trends towards digital transformation.
• The increase in dividend payout reflects a commitment to shareholder returns, which is a common practice among established players in the healthcare sector.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased dividend and potential for future growth.
• Employees will continue to contribute to the company's success and growth.
• Customers will benefit from Cencora's expanded services and solutions.
• Suppliers will continue to partner with Cencora in the pharmaceutical supply chain.
• Creditors will be reassured by the company's strong financial performance and outlook.

Next Steps

• Cencora will integrate Retina Consultants of America into its operations.
• The company will focus on executing its fiscal year 2025 growth strategy.
• Cencora management will attend several investor conferences in the coming months.
• The company will continue to monitor and manage the impact of market trends and economic conditions on its business.

Key Dates

Keywords

Cencora, pharmaceutical distribution, healthcare solutions, revenue, earnings per share, EPS, dividend, acquisition, Retina Consultants of America, financial results, fiscal year 2024, fiscal year 2025, operating income, non-GAAP, GLP-1, goodwill impairment